EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 217 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Child With Cancer Becomes Honorary First Responder July 15, 2019 Reunión anual de la American Society of Clinical Oncology de 2023:... June 2, 2023 How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 A tribute to Dame Valerie Beral October 13, 2022 Load more HOT NEWS Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption How and When to Wash Your Reusable Cloth Mask and When... Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers A Message from the ESMO President
